The value of survival gains from therapeutic innovations for US patients with relapsed/refractory multiple myeloma

AIMS: This study quantifies the value of survival gains attributable to novel treatments approved since 2003 for United States (US) patients with relapsed/refractory multiple myeloma (RRMM). METHODS: We estimated the increase in survival attributable to lenalidomide and bortezomib for multiple myelo...

Descripción completa

Detalles Bibliográficos
Autores principales: MacEwan, Joanna P, Majer, Istvan, Chou, Jacquelyn W, Panjabi, Sumeet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255558/
https://www.ncbi.nlm.nih.gov/pubmed/34276923
http://dx.doi.org/10.1177/20406207211027463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255558/
https://www.ncbi.nlm.nih.gov/pubmed/34276923
http://dx.doi.org/10.1177/20406207211027463

Ejemplares similares